Literature DB >> 18639282

Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma.

Akio Horiguchi1, Tomohiko Asano, Takako Asano, Keiichi Ito, Makoto Sumitomo, Masamichi Hayakawa.   

Abstract

PURPOSE: Fatty acid synthase is a key enzyme in the de novo biosynthesis of fatty acids. Increased fatty acid synthase expression and its association with tumor aggressiveness and poor prognosis have been demonstrated in various human malignant tumors. We investigated fatty acid synthase expression in patients with renal cell carcinoma and its impact on clinicopathological parameters.
MATERIALS AND METHODS: Fatty acid synthase expression in 120 patients with renal cancer was examined by immunohistochemistry. The relationship between fatty acid synthase expression status and various clinicopathological parameters was analyzed. Survival analysis was performed using the log rank test and a Cox multivariate hazard model.
RESULTS: Of 120 tumors 18 (15%) showed positive fatty acid synthase expression, which was significantly associated with advanced pathological T stage (pT3-4, p = 0.0009), regional lymph node metastasis (p = 0.0429), distant metastasis (p = 0.0042), higher histological grade (G3, p = 0.0017) and microvascular invasion (p = 0.0357). Patients with positive fatty acid synthase expression had significantly shorter cancer specific survival than those with negative FAS expression (p <0.0001). Multivariate Cox proportional hazards model analysis demonstrated that positive fatty acid synthase expression was an independent predictor of shortened cancer specific survival (p = 0.0363, HR 3.736).
CONCLUSIONS: Increased FAS expression could be an indicator of tumor aggressiveness and poor prognosis of renal cell carcinoma. Patients with fatty acid synthase positive tumors should be followed closely and carefully, and adjuvant therapy should be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639282     DOI: 10.1016/j.juro.2008.04.135

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  51 in total

1.  PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.

Authors:  Omran Abu Aboud; Dallas Donohoe; Scott Bultman; Mark Fitch; Tim Riiff; Marc Hellerstein; Robert H Weiss
Journal:  Am J Physiol Cell Physiol       Date:  2015-03-25       Impact factor: 4.249

2.  Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

Authors:  Laurence Albiges; A Ari Hakimi; Wanling Xie; Rana R McKay; Ronit Simantov; Xun Lin; Jae-Lyun Lee; Brian I Rini; Sandy Srinivas; Georg A Bjarnason; Scott Ernst; Lori A Wood; Ulka N Vaishamayan; Sun-Young Rha; Neeraj Agarwal; Takeshi Yuasa; Sumanta K Pal; Aristotelis Bamias; Emily C Zabor; Anders J Skanderup; Helena Furberg; Andre P Fay; Guillermo de Velasco; Mark A Preston; Kathryn M Wilson; Eunyoung Cho; David F McDermott; Sabina Signoretti; Daniel Y C Heng; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

3.  Fatty acid synthase overexpression in adult testicular germ cell tumors: potential role in the progression of non-seminomatous germ cell tumors.

Authors:  Kosuke Miyai; Keiichi Iwaya; Tomohiko Asano; Seiichi Tamai; Osamu Matsubara; Hitoshi Tsuda
Journal:  Virchows Arch       Date:  2013-12-14       Impact factor: 4.064

4.  Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.

Authors:  Edward Sanders; Svenja Diehl
Journal:  Oncoscience       Date:  2015-02-17

Review 5.  Metabolic reprogramming in clear cell renal cell carcinoma.

Authors:  Hiromi I Wettersten; Omran Abu Aboud; Primo N Lara; Robert H Weiss
Journal:  Nat Rev Nephrol       Date:  2017-05-08       Impact factor: 28.314

Review 6.  Radiomics in Kidney Cancer: MR Imaging.

Authors:  Alberto Diaz de Leon; Payal Kapur; Ivan Pedrosa
Journal:  Magn Reson Imaging Clin N Am       Date:  2019-02       Impact factor: 2.266

7.  Fatty acid synthase (FASN) levels in serum of colorectal cancer patients: correlation with clinical outcomes.

Authors:  Qi-qiang Long; Yong-xiang Yi; Jie Qiu; Chuan-jun Xu; Pei-lin Huang
Journal:  Tumour Biol       Date:  2014-01-17

8.  Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation of sterol regulatory element binding protein-1 and activation of acetyl CoA carboxylase.

Authors:  Mazhar Al-Zoubi; Galina Chipitsyna; Shivam Saxena; Konrad Sarosiek; Ankit Gandhi; Christopher Y Kang; Daniel Relles; Jocelyn Andrelsendecki; Terry Hyslop; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

Review 9.  The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors.

Authors:  Laura M Deford-Watts; Akiva Mintz; Steven J Kridel
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

10.  Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

Authors:  Angelika Tölle; Monika Jung; Michael Lein; Manfred Johannsen; Kurt Miller; Holger Moch; Klaus Jung; Glen Kristiansen
Journal:  BMC Cancer       Date:  2009-07-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.